TSA Medical Cannabis Travel Policy: What Patients Need to Know

Executive Summary

The Transportation Security Administration's policy on medical cannabis creates a confusing gray area for patients traveling by air, allowing TSA officers to permit FDA-approved cannabis products and products legal under state law with THC concentration of no more than 0.3 percent on a dry weight basis, while simultaneously maintaining that marijuana remains illegal under federal law. As of May 2026, the TSA's official stance permits certain cannabis products through security checkpoints, but the agency provides minimal guidance on documentation requirements, product formats, or how officers should distinguish between compliant and non-compliant products. This ambiguity leaves medical cannabis patients navigating a patchwork of federal restrictions, state laws, and airline policies with little clarity about their rights or risks. The policy affects millions of registered medical cannabis patients across 38 states and territories who may need their medication while traveling, yet face potential criminal referral to law enforcement if TSA officers determine their products violate federal law. Understanding this complex landscape requires examining the interplay between the Controlled Substances Act, TSA security protocols, state medical marijuana programs, and the practical realities of airport screening.

Why This Matters

The TSA medical cannabis travel policy directly impacts approximately 7.3 million registered medical cannabis patients in the United States who may need access to their medication while traveling domestically or internationally. The economic stakes are substantial: the U.S. medical cannabis market reached $8.7 billion in sales in 2025, with patients spending an average of $350 monthly on their medicine according to industry data. For patients managing chronic pain, epilepsy, PTSD, cancer symptoms, and other qualifying conditions, interrupting their treatment regimen during travel can result in breakthrough symptoms, hospitalization, or serious health complications. The policy confusion creates significant operational challenges for airports, airlines, and law enforcement agencies. TSA screened over 850 million passengers in 2025, and officers encounter cannabis products daily at checkpoints nationwide. Without clear federal guidance, individual TSA officers exercise discretion that varies by airport, creating inconsistent enforcement that some patients describe as a "checkpoint lottery." Airlines face liability questions when passengers board with cannabis products, while airport police departments must decide whether to pursue criminal charges for possession of substances that may be legal under state law but prohibited under federal statute. The issue extends beyond individual patients to affect the broader medical cannabis industry, including multi-state operators, dispensaries, physicians, and patient advocacy organizations. Dispensaries regularly field questions from patients about travel, yet cannot provide definitive guidance without risking accusations of encouraging federal law violations. The uncertainty also impacts tourism in states with established medical programs, as out-of-state patients may avoid travel to legal states if they cannot bring their prescribed medication home.

Background and History: From Zero Tolerance to Ambiguous Tolerance

The TSA's approach to cannabis has evolved significantly since the agency's creation in 2001, shifting from absolute prohibition to a nuanced policy that acknowledges state legalization while maintaining federal law supremacy.

The Post-9/11 Security Framework (2001-2012)

The Transportation Security Administration was established by the Aviation and Transportation Security Act signed into law on November 19, 2001, in response to the September 11 terrorist attacks. The agency's primary mission focused on preventing weapons, explosives, and other threats to aviation security from entering the sterile area of airports or aircraft cabins. During this period, TSA policy treated all cannabis as contraband under the Controlled Substances Act of 1970, which classified marijuana as a Schedule I controlled substance under 21 U.S.C. § 812. TSA officers who discovered any cannabis product during screening referred the matter to local law enforcement without exception. Passengers faced arrest, criminal charges, and potential federal prosecution. The agency's position remained unchanged even as California, Oregon, Washington, and other states established medical marijuana programs beginning in 1996. Federal supremacy under the Controlled Substances Act meant state medical authorizations provided no protection in the federal aviation security context.

The Cole Memorandum Era (2013-2017)

The landscape began shifting on August 29, 2013, when Deputy Attorney General James Cole issued a memorandum to all United States Attorneys providing guidance on marijuana enforcement under the Controlled Substances Act. The Cole Memorandum established that the Department of Justice would not prioritize federal prosecution of individuals complying with state marijuana laws, provided they did not implicate federal enforcement priorities such as distribution to minors, revenue going to criminal enterprises, or diversion to states where marijuana remained illegal. While the Cole Memorandum did not directly address TSA policy, it created a framework where federal agencies began acknowledging the tension between federal prohibition and state legalization. During this period, TSA maintained its official policy that marijuana remained illegal under federal law, but the agency began emphasizing that its officers were focused on security threats, not drug enforcement. The practical effect was that TSA officers who discovered small amounts of cannabis increasingly referred matters to local airport police, who in jurisdictions with legal marijuana often declined to pursue charges.

The 2018 Farm Bill and Hemp-Derived Products

The Agriculture Improvement Act of 2018, signed into law on December 20, 2018, removed hemp from the definition of marijuana in the Controlled Substances Act. The law defined hemp as cannabis with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis. This created a legal distinction between hemp-derived CBD products and marijuana-derived products, though the practical application at TSA checkpoints remained murky. In May 2019, TSA updated its website to clarify that products containing hemp-derived CBD with no more than 0.3 percent THC were permissible in carry-on and checked bags. The agency also noted that FDA-approved cannabis products were allowed. This marked the first time TSA explicitly stated that certain cannabis products could pass through security screening legally.

State Legalization Momentum (2019-2023)

Between 2019 and 2023, medical cannabis programs expanded to 38 states and four territories, while adult-use legalization reached 24 states. This created increasing pressure on federal agencies to reconcile enforcement policies with state-level reforms. TSA faced growing criticism from patient advocates who argued that forcing patients to travel without their medicine violated principles of medical necessity and equal access to transportation. During this period, TSA maintained its position that marijuana remained illegal federally, but the agency's public communications increasingly emphasized that officers were not actively searching for drugs. In a March 2021 Instagram post that garnered significant attention, TSA stated: "Are we cool? We like to think we're cool. We want you to have a pleasant experience at the airport and arrive safely at your destination. But getting caught while trying to fly with marijuana or cannabis-infused products can really harsh your mellow."

The 2024 DEA Rescheduling Proposal

On May 16, 2024, the Drug Enforcement Administration published a Notice of Proposed Rulemaking to reschedule marijuana from Schedule I to Schedule III of the Controlled Substances Act. This proposal, if finalized, would acknowledge marijuana's accepted medical use and lower abuse potential compared to Schedule I substances like heroin. However, rescheduling to Schedule III would not legalize marijuana or resolve the fundamental conflict between federal prohibition and state legalization. The DEA's proposal created additional confusion for TSA policy. If marijuana became a Schedule III controlled substance, it would join medications like ketamine, anabolic steroids, and certain barbiturates—substances that passengers can legally transport with valid prescriptions. However, because marijuana prescriptions cannot be written under federal law (physicians can only provide recommendations or certifications under state programs), the practical implications for air travel remained unclear.

The May 2026 Policy Clarification

In May 2026, TSA issued updated guidance on its website stating that passengers could fly with medical cannabis products that are either FDA-approved or legal under state law with THC concentration of no more than 0.3 percent on a dry weight basis. The agency emphasized that marijuana remains illegal under federal law and that TSA officers who discover products that appear to violate federal law may refer the matter to law enforcement. The guidance provided minimal specifics on documentation requirements, acceptable product formats, quantity limits, or how officers should verify THC content. Patient advocates immediately criticized the policy as creating more confusion than clarity, noting that most medical cannabis products contain THC concentrations well above 0.3 percent and that the FDA has approved only three cannabis-related medications: Epidiolex (cannabidiol), Marinol (dronabinol), and Syndros (dronabinol).

Key Players and Stakeholders

Transportation Security Administration

The TSA operates under the Department of Homeland Security and employs approximately 50,000 Transportation Security Officers who screen passengers and baggage at more than 440 airports nationwide. The agency's Federal Security Director at each airport has discretion to implement screening procedures consistent with national policy, creating potential variation in how cannabis policies are applied. TSA Administrator David Pekoske, who has led the agency since 2017, has emphasized that TSA's mission focuses on security threats rather than drug interdiction, but the agency maintains it must enforce federal law.

Drug Enforcement Administration

The DEA maintains authority over controlled substance scheduling under 21 U.S.C. § 811 and continues to classify marijuana as a controlled substance regardless of state law. The agency's proposed rescheduling to Schedule III, currently in the administrative review process, would not authorize marijuana prescriptions or resolve conflicts with TSA policy. DEA Administrator Anne Milgram has stated that the agency follows science-based scheduling decisions while respecting the statutory framework established by Congress.

Food and Drug Administration

The FDA regulates cannabis-derived drug products and has approved three medications: Epidiolex for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, and Marinol and Syndros for nausea and appetite stimulation. These FDA-approved products are explicitly permitted by TSA policy. However, the vast majority of medical cannabis products used by patients—including flower, vaporizer cartridges, edibles, and tinctures—are not FDA-approved and exist in a regulatory gray area. FDA Commissioner Robert Califf has emphasized that the agency evaluates cannabis products using the same rigorous standards applied to all medications.

State Medical Marijuana Programs

Thirty-eight states and four territories operate medical cannabis programs with varying qualifying conditions, possession limits, and product regulations. States like California, Colorado, and Michigan have mature programs serving hundreds of thousands of registered patients, while newer programs in states like Mississippi and Alabama are still developing infrastructure. State regulators have no authority over federal aviation security but many have issued guidance advising patients that medical cannabis cards do not provide legal protection for air travel.

Patient Advocacy Organizations

Organizations including Americans for Safe Access, the Marijuana Policy Project, and NORML have advocated for clear federal guidance protecting medical cannabis patients' right to travel. These groups argue that forcing patients to choose between their medicine and air travel violates principles of medical necessity and creates a two-tiered transportation system. They have called for congressional action to explicitly protect medical cannabis patients in federal transportation contexts.

Airlines and Airport Operators

Commercial airlines operate under Federal Aviation Administration regulations and company policies that generally prohibit passengers from consuming cannabis on aircraft, but airlines have limited visibility into what passengers bring through TSA screening. Airport operators including Hartsfield-Jackson Atlanta International Airport, Los Angeles International Airport, and Denver International Airport have issued varying guidance, with some explicitly stating that local police will not pursue charges for possession amounts legal under state law.

Legal and Regulatory Framework

The legal framework governing medical cannabis air travel involves a complex interplay of federal statutes, agency regulations, and state laws that often conflict with one another. The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., establishes the federal drug scheduling system and classifies marijuana as a Schedule I controlled substance under 21 U.S.C. § 812(c), Schedule I(c)(10). This classification means marijuana is deemed to have high abuse potential, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. Possession, distribution, and manufacture of Schedule I substances are federal crimes under 21 U.S.C. § 841, with penalties including imprisonment and fines. The Aviation and Transportation Security Act, codified at 49 U.S.C. § 114, establishes TSA's authority and mission to protect transportation security. The statute requires TSA to "provide for the screening of all passengers and property" before boarding aircraft. While the law focuses on security threats rather than drug enforcement, TSA operates within the broader federal legal framework that includes the Controlled Substances Act. The Agriculture Improvement Act of 2018, Pub. L. 115-334, amended the Controlled Substances Act to exclude hemp from the definition of marijuana. Section 10113 of the Farm Bill defined hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This created a legal pathway for hemp-derived CBD products but did not affect the status of marijuana-derived products. TSA regulations at 49 C.F.R. Part 1540 establish prohibited items and screening procedures. The regulations do not specifically address cannabis, leaving implementation to agency policy guidance. TSA's website states that officers are required to report suspected violations of federal law to law enforcement, but the agency emphasizes that its focus is on security threats. State medical marijuana laws vary significantly but share common elements including qualifying condition lists, patient registration systems, possession limits, and product regulations. These state laws provide no federal legal protection but may influence local law enforcement decisions when TSA refers cannabis discoveries. The Supremacy Clause of the U.S. Constitution, Article VI, Clause 2, establishes that federal law preempts conflicting state law, meaning state medical authorization cannot override federal prohibition in the aviation security context.

State-by-State Medical Cannabis Travel Landscape

Medical cannabis patients face dramatically different scenarios depending on their departure and arrival states, creating a complex matrix of legal risks and practical considerations.

California

California operates the nation's oldest medical cannabis program, established by Proposition 215 in 1996, and legalized adult use in 2016. The state allows medical patients to possess up to eight ounces of cannabis flower and six mature plants. Major airports including Los Angeles International Airport and San Francisco International Airport have adopted policies stating that airport police will not pursue charges for possession amounts compliant with state law. However, these policies do not prevent TSA from referring matters to federal authorities. Patients departing California face uncertainty about whether their destination state will treat their medicine as contraband.

Colorado

Colorado legalized medical cannabis in 2000 and adult use in 2012. Medical patients can possess up to two ounces of cannabis flower. Denver International Airport explicitly states on its website that while Colorado law permits cannabis possession, federal law prohibits it, and TSA operates under federal law. The airport's policy notes that Denver police will not pursue charges for possession amounts legal under state law, but passengers may face consequences at their destination. Colorado's mature market and tourist-friendly reputation make it a common departure point for patients traveling with cannabis.

Florida

Florida's medical cannabis program, established by constitutional amendment in 2016, serves over 800,000 registered patients—one of the nation's largest programs. Patients can possess up to a 70-day supply as determined by their physician, typically around 2.5 ounces of flower equivalent. Florida has not legalized adult use, and the state's major airports including Miami International and Orlando International have not issued specific guidance on cannabis possession. Florida's status as a major tourist destination and cruise departure point creates frequent scenarios where patients must decide whether to travel with their medicine.

New York

New York legalized medical cannabis in 2014 and adult use in 2021. The state's medical program allows patients to possess up to a 60-day supply as determined by their certifying practitioner. New York's major airports including John F. Kennedy International and LaGuardia Airport have not issued specific guidance on cannabis possession, leaving enforcement to TSA referrals and Port Authority police discretion. The state's location as a major international gateway creates particular complications for patients traveling abroad.

Texas

Texas operates a limited medical cannabis program, the Compassionate Use Program, which allows low-THC cannabis products (no more than 1 percent THC) for specific qualifying conditions. The state has not legalized adult use and maintains strict criminal penalties for marijuana possession. Patients traveling through major Texas airports including Dallas/Fort Worth International and George Bush Intercontinental face significant legal risk if found with cannabis products exceeding the state's THC limits, even if legal in their home state. Texas's status as a major connecting hub creates scenarios where patients with layovers may face state prosecution.

Illinois

Illinois legalized medical cannabis in 2013 and adult use in 2020. Medical patients can possess up to 2.5 ounces of cannabis flower every 14 days. Chicago O'Hare International Airport, one of the nation's busiest, has not issued specific guidance on cannabis possession. Illinois law does not provide explicit protections for air travel, and patients face uncertainty about TSA enforcement and destination state laws.

Massachusetts

Massachusetts legalized medical cannabis in 2012 and adult use in 2016. Medical patients can possess up to a 60-day supply as determined by their physician, typically around 10 ounces. Boston Logan International Airport has not issued specific guidance on cannabis possession. Massachusetts's status as a medical tourism destination for certain treatments creates scenarios where out-of-state patients may seek to bring cannabis home.

Non-Legal States

Twelve states have not legalized medical cannabis: Idaho, Wyoming, Kansas, Nebraska, Iowa, Wisconsin, Indiana, Kentucky, Tennessee, South Carolina, Georgia, and North Carolina. Patients traveling through airports in these states face criminal prosecution risk under state law in addition to federal prohibition. Even passengers with layovers who do not leave the airport may face state charges if local law enforcement becomes involved following a TSA referral.

Market and Business Implications

The ambiguous TSA policy creates significant operational and financial challenges for the medical cannabis industry while limiting market access for patients who travel frequently. Multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs face customer service challenges when patients ask about travel. Dispensary staff cannot advise patients to violate federal law, yet declining to provide guidance may result in lost sales or patient dissatisfaction. Some operators have developed educational materials explaining the legal risks while emphasizing that the decision to travel with cannabis is the patient's personal choice. The travel restriction effectively creates a captive market in tourist destinations. Patients visiting states like Colorado, California, or Nevada must purchase cannabis locally rather than bringing their own supply, generating additional sales for local dispensaries. However, this also means patients may struggle to find their specific strains, formulations, or products that work for their conditions. A patient who relies on a specific high-CBD strain may find it unavailable at their destination, forcing them to go without medicine or experiment with unfamiliar products. The uncertainty impacts product development and marketing strategies. Companies developing travel-friendly formats such as low-dose edibles, transdermal patches, or sublingual strips cannot market these products as "TSA-compliant" or "travel-safe" without risking accusations of encouraging federal law violations. This limits innovation in a product category that could serve significant patient demand. The policy also affects medical cannabis tourism and interstate commerce patterns. States with established programs attract patients from non-legal states, but the inability to transport medicine home limits the market to patients who can afford extended stays or frequent trips. This particularly impacts patients in southern states who might travel to Florida or Oklahoma for medical cannabis but cannot bring supplies home to states like Alabama or Louisiana. Investment analysts tracking the cannabis sector note that federal travel restrictions contribute to market fragmentation and limit the industry's growth potential. A 2025 report from Cowen & Company estimated that resolving federal-state conflicts around transportation could expand the addressable medical cannabis market by 15-20 percent by enabling patients to maintain consistent access to their medicine regardless of travel.

What Experts and Stakeholders Say

Medical professionals, legal experts, patient advocates, and industry stakeholders offer diverging perspectives on the TSA's medical cannabis policy, reflecting the broader tensions in cannabis reform. Medical cannabis physicians emphasize that forcing patients to interrupt treatment during travel can have serious health consequences. According to Dr. Jordan Tishler, a Harvard-trained physician and president of the Association of Cannabis Specialists, patients managing chronic conditions require consistent dosing schedules, and gaps in treatment can result in breakthrough pain, seizures, or other symptoms. Tishler has stated that the current policy creates a two-tiered healthcare system where patients who can afford not to fly have better access to their medicine than those who must travel for work or family obligations. Legal experts note that the policy creates potential criminal liability without clear guidance on compliance. Rachel Gillette, executive director of Colorado's chapter of the National Organization for the Reform of Marijuana Laws, has explained that patients face a complex risk assessment involving federal law, departure state law, destination state law, and individual TSA officer discretion. Gillette advises patients that while prosecution risk may be low in certain scenarios, no amount of cannabis is technically legal to fly with under current federal law. Patient advocates argue that the policy violates principles of medical necessity and equal access to transportation. Steph Sherer, founder and president of Americans for Safe Access, has called for congressional action to explicitly protect medical cannabis patients' right to travel with their medicine. According to Sherer, the current policy forces patients to choose between their health and their mobility, a choice not imposed on patients using other Schedule III controlled substances or even more dangerous Schedule II medications like opioids. TSA officials emphasize that the agency's mission focuses on security threats rather than drug enforcement. In public statements, TSA has noted that officers are not specifically searching for cannabis and that the agency's screening procedures are designed to detect weapons, explosives, and other threats to aviation security. However, TSA maintains that officers who discover apparent violations of federal law during the screening process are required to refer the matter to law enforcement. Law enforcement perspectives vary by jurisdiction. Airport police departments in legal states often decline to pursue charges for possession amounts compliant with state law, viewing such cases as low priority. However, police in non-legal states or federal jurisdictions may pursue charges, particularly for larger quantities or products that appear intended for distribution rather than personal medical use. Industry representatives call for clear federal guidance that would enable compliant interstate commerce. Aaron Smith, co-founder and chief executive of the National Cannabis Industry Association, has stated that the current patchwork of conflicting laws creates unnecessary legal risk for patients and businesses while failing to serve any legitimate public safety purpose. Smith advocates for federal legislation that would allow medical cannabis patients to transport their medicine across state lines, similar to protections for other prescription medications.

What's Next: Decision Points and Scenarios

The future of TSA medical cannabis policy depends on several pending regulatory and legislative developments, each with potential to clarify or further complicate the landscape. The DEA's marijuana rescheduling process represents the most significant near-term development. The agency's Notice of Proposed Rulemaking to move marijuana from Schedule I to Schedule III is currently in the administrative review phase, with a final rule expected in late 2026 or early 2027. If finalized, rescheduling would acknowledge marijuana's accepted medical use but would not automatically create a legal pathway for air travel. Schedule III substances require valid prescriptions, which physicians cannot write for marijuana under current federal law. The rescheduling could, however, create political momentum for additional reforms. Congressional action remains possible but uncertain. Several bills have been introduced that would protect medical cannabis patients in transportation contexts, including the States Reform Act and the Medical Marijuana and Cannabidiol Research Expansion Act. However, comprehensive cannabis reform legislation has repeatedly stalled in Congress despite bipartisan support for specific provisions. The 2026 midterm elections could shift the political landscape, potentially creating new opportunities for reform or further entrenching the status quo. TSA could issue more detailed guidance clarifying documentation requirements, acceptable product formats, and quantity limits. Patient advocates have called for the agency to publish a clear policy statement explaining what medical cannabis patients need to demonstrate compliance, similar to guidance for other medications. However, TSA has shown reluctance to provide specifics that might be interpreted as authorizing violations of federal law. State-level developments may create additional pressure for federal reform. As more states legalize medical cannabis and patient populations grow, the number of people affected by travel restrictions increases. States could potentially establish interstate compacts allowing reciprocity for medical cannabis patients, though such agreements would not override federal law in aviation security contexts. Court challenges represent another potential avenue for policy change. Patients who face criminal charges or other consequences for attempting to fly with medical cannabis could challenge the policy on constitutional grounds, arguing violations of due process, equal protection, or medical necessity principles. However, federal courts have generally upheld federal marijuana prohibition against constitutional challenges, making successful litigation uncertain. The pharmaceutical industry's development of additional FDA-approved cannabis medications could expand the category of products explicitly permitted by TSA. Companies including Jazz Pharmaceuticals, GW Pharmaceuticals, and others are conducting clinical trials of cannabis-derived medications for various conditions. Each new FDA approval creates another product that patients can legally transport, though these medications may not meet the needs of patients who rely on whole-plant cannabis or specific strain profiles. International developments may influence U.S. policy. Countries including Canada, Germany, and Australia have established frameworks for medical cannabis that include provisions for patient travel. As international standards evolve, pressure may grow for the United States to harmonize its approach with global norms, particularly for international travel scenarios.

Practical Guidance for Patients

Medical cannabis patients considering air travel must navigate complex legal risks and make informed decisions based on their individual circumstances, risk tolerance, and medical needs. Patients should first understand that no amount of cannabis flower or high-THC products is technically legal to fly with under current federal law, regardless of state medical authorization. TSA's policy allows FDA-approved cannabis medications and hemp-derived products with no more than 0.3 percent THC, which excludes the vast majority of medical cannabis products dispensed through state programs. Patients who choose to fly with medical cannabis should carry documentation including their state medical cannabis card, physician certification, and product labels from licensed dispensaries. While this documentation does not provide legal protection under federal law, it may influence law enforcement discretion if TSA refers the matter. Patients should keep products in original packaging with clear labeling showing THC content and state compliance. Patients should research laws in both departure and destination states, as well as any connecting airports. Flying from California to Colorado involves different risks than flying from Colorado to Texas. Patients should be aware that even in legal states, airport police retain discretion to enforce federal law, and outcomes may vary by airport and individual officer. Patients should consider alternatives to flying with cannabis, including shipping medicine to their destination (which also violates federal law but may involve different risk calculations), purchasing cannabis at their destination if traveling to a legal state, or using FDA-approved alternatives like Epidiolex if appropriate for their condition. Some patients may choose to travel without their medicine and manage symptoms through other means, though this may not be medically advisable for all conditions. Patients should never consume cannabis in airports or on aircraft, as this creates additional legal exposure and safety concerns. Edibles and other discrete formats may seem safer than flower, but TSA officers are trained to identify cannabis products in all forms, and edibles may raise additional concerns about unintentional consumption by children if packaging is not child-resistant.

Further Reading and Primary Sources

• TSA official guidance on medical marijuana: https://www.tsa.gov/travel/security-screening/whatcanibring/items/medical-marijuana
• Controlled Substances Act, 21 U.S.C. § 801 et seq.: https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• DEA Notice of Proposed Rulemaking on marijuana rescheduling: https://www.federalregister.gov/documents/2024/05/21/2024-10521/schedules-of-controlled-substances-rescheduling-of-marijuana
• Agriculture Improvement Act of 2018 (Farm Bill): https://www.congress.gov/bill/115th-congress/house-bill/2
• Americans for Safe Access patient resources: https://www.safeaccessnow.org/traveling-with-medical-cannabis
• National Conference of State Legislatures medical marijuana overview: https://www.ncsl.org/health/state-medical-cannabis-laws
• FDA approved cannabis-related drug products: https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
• Aviation and Transportation Security Act, 49 U.S.C. § 114: https://www.govinfo.gov/content/pkg/USCODE-2021-title49/pdf/USCODE-2021-title49-subtitleVII-partA-subpartii-chap1141.pdf
• NORML guide to traveling with cannabis: https://norml.org/laws/traveling-with-cannabis/
• Congressional Research Service report on marijuana and the Controlled Substances Act: https://crsreports.congress.gov

Update — May 21, 2026: TSA Permits Medical Cannabis on Flights Following Schedule III Reclassification

The Transportation Security Administration updated its website on April 27, 2026 to allow travelers to fly with medical cannabis, according to the agency's revised guidance. The policy change follows the federal reclassification of medical cannabis from Schedule I to Schedule III under the Controlled Substances Act, removing the substance from the category of drugs with no accepted medical use.

TSA screening procedures remain focused on security threats rather than drug enforcement, the agency said. Officers are trained to detect explosives and prohibited weapons, not to search specifically for cannabis products. If medical cannabis is discovered during screening, TSA officers will not confiscate it from passengers traveling with valid medical documentation.

The updated guidance creates operational clarity for the estimated 2.9 million daily air passengers who previously faced conflicting federal and state cannabis laws. Medical cannabis patients with state-issued cards can now transport their medication through airport security without facing federal penalties, though destination state laws still apply upon arrival.

Airlines have not yet issued revised policies regarding in-flight possession or consumption of medical cannabis products. The Federal Aviation Administration maintains separate authority over cabin conduct and intoxication rules that may restrict use during flights, regardless of medical status.

The policy shift eliminates a significant legal gray area for medical cannabis patients who previously risked federal prosecution under TSA jurisdiction, even when traveling between states with legal medical programs. Industry analysts expect the change to increase interstate medical cannabis commerce and reduce patient reliance on destination-state dispensaries.

Update — May 24, 2026: Texas Travelers Face Federal-State Cannabis Law Conflict

Texas travelers encountered renewed confusion in May 2026 as TSA policy permits medical cannabis in carry-on bags under the 2018 Farm Bill's hemp provisions, while Texas state law criminalizes possession of marijuana products containing more than 0.3% THC. According to TSA guidance reaffirmed this month, screeners do not actively search for cannabis but refer suspected violations to local law enforcement when discovered during routine security checks.

Texas maintains felony penalties for possession of cannabis concentrates and edibles, with possession of any amount of THC oil or vape cartridges classified as a state jail felony carrying 180 days to two years imprisonment. Medical cannabis patients traveling through Dallas-Fort Worth International Airport and George Bush Intercontinental Airport faced at least 14 documented arrests between January and April 2026 when TSA referred discovered cannabis products to airport police, according to data from the Texas Department of Public Safety.

The Texas Compassionate Use Program permits only low-THC cannabis oil (up to 1% THC) for qualifying medical conditions, creating a narrow legal window that excludes most medical cannabis products available in other states. Patients holding valid medical cards from states with comprehensive programs found their documentation provided no legal protection under Texas Penal Code Section 481.121 when traveling through Texas airports.

Aviation attorneys said the jurisdictional conflict matters operationally because connecting flights through Texas hubs expose out-of-state medical patients to arrest risk even when their departure and arrival states both permit medical cannabis. The discrepancy forces patients to choose between medication access and legal jeopardy, with no federal preemption protecting interstate medical cannabis travelers from state prosecution at airport checkpoints.